Limited number of Streptococcus pneumoniae serotypes cause most invasive pneumococcal disease

Oct 05, 2010

Contrary to current thinking, the group of serotypes of Streptococcus pneumoniae responsible for most invasive pneumococcal disease worldwide is conserved across regions. Streptococcus pneumoniae is the leading bacterial cause of pneumonia, sepsis, and meningitis in children, which together comprise more than 25% of the 10 million deaths estimated to have occurred in 2000 in children under 5 years of age, and preventable by access to appropriate vaccines.

The serotypes currently included in existing pneumococcal formulations account for 49-88% of deaths in under 5 in Africa and Asia, where the morbidity and mortality of pneumococcal disease are the highest, and where until recently, most children do not have access to current pneumococcal conjugate vaccines. These are the key findings of a research study in this week's by Hope Johnson from the International Vaccine Access Center, Johns Hopkins University Bloomberg School of Public Health, Baltimore, USA, and colleagues.

After an extensive literature review, which included information on 60,090 isolates of from 70 countries, the authors estimated which serotypes caused invasive pneumococcal disease among children under five in different regions of the world. They found that found seven serotypes (1, 5, 6A, 6B, 14, 19F, and 23F) were the most common globally and that these seven serotypes accounted for the majority of invasive pneumococcal disease in every region.

These important findings mean that health policy makers can assess the potential impact of serotypes included in different conjugate vaccines and vaccine manufacturers can now work from a consensus set of serotype coverage estimates to plan and design future serotype-based formulations to target local pneumococcal disease burden more accurately.

The authors say: "Our findings contradict the conventional supposition that the most common serotypes causing [invasive pneumococcal disease] vary greatly across geographic regions."

They add: "Recent progress towards increasing access to pneumococcal conjugate vaccines in high-burden countries will contribute to achieving the year 2015 Millennium Development Goal 4 target to reduce child mortality by two-thirds."

Explore further: Haiti cholera outbreak kills 132 in 2014

More information: Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, et al. (2010) Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project. PLoS Med 7(10): e1000348. doi:10.1371/journal.pmed.1000348

add to favorites email to friend print save as pdf

Related Stories

Pneumococcal disease rates down significantly post-vaccine

Mar 18, 2008

Since the approval of a vaccine against pneumococcal bacteria for young children in 2000, rates of invasive pneumococcal disease (IPD) are down significantly in all age groups, while rates of IPD caused by non-vaccine strains ...

Recommended for you

Ebola vaccine promising in first human trials

10 hours ago

Researchers say they are one step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.

At one month, US Ebola monitors finding no cases

13 hours ago

The U.S. program that requires weeks of monitoring for travelers from African countries with Ebola reaches the one-month mark Thursday. And so far, no cases of the disease have turned up.

EU calls for 5,000 doctors to fight Ebola

14 hours ago

The European Commission called for 5,000 doctors to be sent from EU states to combat west Africa's Ebola epidemic, a European source with knowledge of the matter said on Wednesday.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.